During the last session, Bicara Therapeutics Inc (NASDAQ:BCAX)’s traded shares were 0.33 million. At the end of the trading day, the stock’s price was $11.60, reflecting an intraday loss of -3.05% or -$0.37. The 52-week high for the BCAX share is $28.09, that puts it down -142.16 from that peak though still a striking 0.78% gain since the share price plummeted to a 52-week low of $11.51. The company’s market capitalization is $631.49M, and the average intraday trading volume over the past 10 days was 0.37 million shares, and the average trade volume was 415.74K shares over the past three months.

Bicara Therapeutics Inc (NASDAQ:BCAX) trade information

Bicara Therapeutics Inc (BCAX) registered a -3.05% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -3.05% in intraday trading to $11.60, hitting a weekly high. The stock’s 5-day price performance is -2.31%, and it has moved by -34.03% in 30 days. The short interest in Bicara Therapeutics Inc (NASDAQ:BCAX) is 4.52 million shares and it means that shorts have 7.93 day(s) to cover.

The consensus price target of analysts on Wall Street is $35, which implies an increase of 66.86% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $35 and $35 respectively. As a result, BCAX is trading at a discount of -201.72% off the target high and -201.72% off the low.

BCAX Dividends

Bicara Therapeutics Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Also, the Mutual Funds coming in first place with the largest holdings of Bicara Therapeutics Inc (BCAX) shares are Price (T.Rowe) New Horizons Fund and AB Cap Fd.-AB Small Cap Growth Port . Data provided on Sep 30, 2024 indicates that Price (T.Rowe) New Horizons Fund owns about 589.53 shares. This amounts to just over 1.08 percent of the company’s overall shares, with a $6.84 million market value. The same data shows that the other fund manager holds slightly less at 410.71, or about 0.75% of the stock, which is worth about $4.77 million.